CUPRINA HOLDINGS CAYMAN-A
CUPRNASDAQ🏆 #5024 by market capUS Equity
$1.82▲ $0.01 (+0.55%)
Market closed · at closeTrack CUPR
Get earnings, price moves & breaking news on Telegram
24h▲ 0.6%
7d▼ 4.2%
14d▼ 6.2%
30d▼ 9.5%
ytd▼ 43.5%
1y▼ 74.7%
🏦Market Cap
$5M
Small Cap
📈Revenue Growth (YoY)
3.3%
Slowing
📊Gross Margin
-32.5%
Thin
💵FCF Margin
-23847.1%
Thin
⚖️P/S Ratio
123.6x
Expensive
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.73 – $1.84
- 52-Week Range
- $1.45 – $14.80
- Volume (shares)
- 8,851
- Avg Volume (shares)
- —
- Shares Outstanding
- 2.7M
- Next Earnings
- —
Fundamentals Snapshot
- Annual Revenue
- $49,894
- Last Q Revenue
- $26,790
- P/E Ratio
- -1.2
- P/S Ratio
- 123.6x
- EPS (TTM)
- $-1.87
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +19.2%
CUPRINA HOLDINGS CAYMAN-A
CUPRFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$50K▲ +3.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-1.3%▼ −79.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$5M▲ +177.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$9M▲ +630.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.7M▲ +19.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▲ +$3M YoY
StockOtter · stockotter.spaceAbout CUPRINA HOLDINGS CAYMAN-A
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.
Latest News & Updates
News unavailable.